Bellicum Pharmaceuticals


BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.

Select Venture Capital & Financial Partners

HillHouse Capital Cormorant Asset Management Sequoia Capital Partners Viking Global Investors Aisling Capital